Company profile
UK company NI039740, incorporated on 29 November 2000.
R&D Antibody Discovery Partner | Fusion Antibodies
Fusion Antibodies offer a complete end-to-end service from antigen design to cell line development. R&D Antibody Discovery Partner.
Company number NI039740
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 May 2025 to 31 Oct 2026
**Targeting DR5: a New Cancer Treatment Strategy** Cancer cells are like rogue agents in the body that don't follow the usual rules. To tackle these dangerous cells, scientists have found a special pathway involving a protein called **Death Receptor 5 (DR5)** (Alternative names: Tumor necrosis factor receptor superfamily member 10B; TNFRSF10B; TRAIL recep...
1 Nov 2024 to 31 Oct 2029
**The Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT)** is a partnership of Life and Health Science (LHS) companies and Academia, aligned to the strategies of both the Departments of Health and Economy of the NI devolved government to enhance health and wealth creation for NI citizens. Currently, NI has a significant presence in ...
1 Feb 2020 to 31 Jul 2021
To develop a new innovative software package for the design of antibody libraries that will be integrated into the service offering provided in antibody engineering, to transform their capabilities and competitiveness.
1 May 2017 to 30 Apr 2020
To develop new innovative processes to create a novel platform technology for the generation and maturation of fully human antibodies that can be rapidly progressed by clients into clinical development.
1 Oct 2016 to 30 Sep 2019
Awaiting Public Project Summary
